Replication FailureOpen accessMedicine· cited by 11

The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial

Johann Bauersachs; Scott D. Solomon; Stefan D. Anker; Isabel Antorrena‐Miranda; Rudolf A. de Boer; Gerasimos Filippatos; Tim Friede; Wilfried Hauke · 2026 · Nature Medicine

WASTE classifies this as Replication Failure · AI classification, approximate

A previously reported effect did not replicate here — verify it holds before you build on it.

Abstract

Abstract MicroRNA-132 (miR-132) is a central regulator of adverse cardiac remodeling. Here we evaluated CDR132L, a synthetic antisense oligonucleotide miR-132 inhibitor, in a multinational, randomized, double-blind, placebo-controlled phase 2 trial (HF-REVERT) in patients with recent myocardial infarction (MI) and left ventricular (LV) systolic dysfunction. Within 3–14 days after MI, 294 patients were randomized to receive CDR132L 5 mg kg −1 , CDR132L 10 mg kg −1 or placebo as three intravenous doses at 4-week intervals plus guideline-directed therapy. In total, 280 patients (245 men and 35 wo

Abstract by Johann Bauersachs; Scott D. Solomon; Stefan D. Anker; Isabel Antorrena‐Miranda; Rudolf A. de Boer; Gerasimos Filippatos; Tim Friede; Wilfried Hauke, Nature Medicine (2026) — licensed CC BY 4.0.

Read the full paper (open access)